Alliqua pulls in $20M to support hydrogel wound care biz

Pennsylvania wound-care specialist Alliqua ($ALQA) pulled in $15 million from a private funding round and another $5.3 million from the exercise of warrants, giving the company a $20.3 million windfall overall. Alliqua intends to funnel the cash into its capital coffers, and in an April 15 release the company also said it is looking to expand its technology lineup through possible acquisitions. Alliqua currently markets its line of hydrogel advanced wound care products, which Seeking Alpha reported earlier this month could grow the company's revenues to $35 million within three years. Release | Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.